Shikonin is a novel and selective IMPDH2 inhibitor that target triple‐negative breast cancer-Reference-Cited by-同舟云学术

Shikonin is a novel and selective IMPDH2 inhibitor that target triple‐negative breast cancer

Published:2020-08-10 Issue:1 Volume:35 Page:463-476
ISSN:0951-418X
Container-title:Phytotherapy Research
language:en
Short-container-title:Phytotherapy Research

Author:

Wang Wanyan¹,Wu Yu¹,Chen Si²,Liu Xi¹,He Jiacheng²,Wang Shuyi²,Lu Weiqiang²,Tang Yong³,Huang Jin¹

Affiliation:

1. State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy East China University of Science and Technology Shanghai China

2. Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences East China Normal University Shanghai China

3. Department of Urology Wuming Hospital of Guangxi Medical University Nanning Guangxi China

Funder

Guangxi Medical University

Publisher

Wiley

Subject

Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ptr.6825

Reference44 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2